5 mins | 30 mins | Hourly | Daily | Weekly |
---|---|---|---|---|
SELL | SELL | SELL | SELL | SELL |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MA5 | 1.16▼ | 1.18▼ | 1.18▼ | 1.25▼ | 1.30▼ |
MA10 | 1.17▼ | 1.18▼ | 1.20▼ | 1.33▼ | 1.28▼ |
MA20 | 1.18▼ | 1.21▼ | 1.23▼ | 1.39▼ | 1.48▼ |
MA50 | 1.18▼ | 1.26▼ | 1.28▼ | 1.34▼ | 2.48▼ |
MA100 | 1.20▼ | 1.30▼ | 1.38▼ | 1.58▼ | 8.42▼ |
MA200 | 1.23▼ | 1.39▼ | 1.34▼ | 2.37▼ | 22.45▼ |
5 mins | 30 mins | Hourly | Daily | Weekly | |
---|---|---|---|---|---|
MACD | -0.002▼ | -0.001▼ | -0.005▼ | -0.032▼ | 0.106▲ |
RSI | 26.629▼ | 27.075▼ | 27.839▼ | 38.694▼ | 35.046▼ |
STOCH | 28.373 | 34.880 | 17.399▼ | 14.006▼ | 30.804 |
WILL %R | -62.500 | -85.000▼ | -89.286▼ | -97.115▼ | -78.873▼ |
CCI | -106.667▼ | -200.494▼ | -110.562▼ | -131.163▼ | -99.144 |
Thursday, June 26, 2025 05:05 AM
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at ...
|
Tuesday, April 01, 2025 10:30 AM
SAN DIEGO, April 01, 2025 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company developing a potentially first-in-class and best-in-class ...
|
Monday, March 31, 2025 05:00 PM
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL – Free Report) – Equities researchers at Leerink Partnrs reduced their Q1 2025 earnings per share estimates for shares of Zentalis Pharmaceuticals ...
|
date | open | high | low | close | volume |
---|---|---|---|---|---|
30/06/25 | 1.22 | 1.23 | 1.145 | 1.16 | 1,142,565 |
27/06/25 | 1.28 | 1.285 | 1.16 | 1.18 | 8,827,500 |
26/06/25 | 1.31 | 1.33 | 1.23 | 1.26 | 1,239,700 |
25/06/25 | 1.34 | 1.37 | 1.295 | 1.31 | 443,000 |
24/06/25 | 1.30 | 1.39 | 1.285 | 1.35 | 641,300 |
23/06/25 | 1.28 | 1.34 | 1.24 | 1.30 | 609,000 |
20/06/25 | 1.39 | 1.405 | 1.24 | 1.30 | 1,285,000 |
18/06/25 | 1.47 | 1.54 | 1.37 | 1.38 | 693,963 |
17/06/25 | 1.51 | 1.51 | 1.41 | 1.50 | 1,295,826 |
16/06/25 | 1.35 | 1.51 | 1.3301 | 1.51 | 920,420 |
|
|
||||
|
|
||||
|
|